Moderna's stock surges as the US government invests millions in covert bird flu vaccine trials, amid concerns over H5N1's spread and potential human-to-human transmission ahead of the presidential elections.
In the New York premarket trading session, Moderna's shares have increased by nearly 4% in response to a Financial Times report stating that the US government is getting ready to "bankroll a late-stage trial of Moderna's mRNA pandemic bird flu vaccine." Ahead of the presidential elec...